CA1222698A - Method of achieving hemostasis, inhibiting fibroplasia, and promoting regeneration in a tissue wound - Google Patents
Method of achieving hemostasis, inhibiting fibroplasia, and promoting regeneration in a tissue woundInfo
- Publication number
- CA1222698A CA1222698A CA000430203A CA430203A CA1222698A CA 1222698 A CA1222698 A CA 1222698A CA 000430203 A CA000430203 A CA 000430203A CA 430203 A CA430203 A CA 430203A CA 1222698 A CA1222698 A CA 1222698A
- Authority
- CA
- Canada
- Prior art keywords
- chitosan
- composition
- solution
- wound
- wounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/36—Materials or treatment for tissue regeneration for embolization or occlusion, e.g. vaso-occlusive compositions or devices
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Materials Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Materials For Medical Uses (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Abstract of the Disclosure The method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration is described wherein a chitosan solution, or chitosan in various solid forms is placed in contact with the tissue wound. The chitosan forms a coagulum which prevents bleeding and negates the formation of a blood clot thereby preventing the formation of fibrin strands. The prevention of the formation of fibrin strands prevents the proliferation of fibroblasts and the synthesis of collagen thereby allowing the promotion of normal tissue regeneration. The process described hereinabove results in wound healing with minimal scar formation.
Description
lZ~1698 Background _ the Invention In applicants' United States Patent No. 4,394,373, a method was described for achieving hemostasis. Since the filing of the United States application, which matured into United States Patent No~ 4,394,373, the inventors have discovered that chitosan may be used to inhibit ibroplasia, and to promote tissue regeneration.
Science has long sought a method to inhibit the synthesis of collagen in wound healing. Much of the work directed to the inhibition of the synthesis of collagen has involved alteration of the biology of collagen by various chemical antagonists. Lower animals do not heal by scar tissue but generate normal structures from pre-existing cells. Usual wound healing begins with a blood clot containing a fibrin network, along which fibroblasts begin the process of fibroplasia~ If blood loss is controlled in the presence of a fibrin clot, fibroblasts will be stimulated. Conversely, if blood loss can be controlled in the absence of a fibrin clot, ~ibroblasts may be not stimulated, and differentiated cells may have the opportunity to replace the lost tissue. It has therefore been found that a material is needed to control blood loss absent the usual blood clot~ing factors, and to allow the ingrowth of normal tissue elements.
Prior art teaches that Chitin and some chitin derivatives accelerate tensile strength of wounds by speeding the fibroblastic synthesis of collagen in the first few days of wound healing. For example, see U. S. Patent Nos.
3,902,268; 3,911,116 and 3,914,413. ThiS topic is also 1~226913 discussed in the May 1970 issue of American Journal of Surgery, pages 560-56~. The subject is further discussed in the June 1969 issue oE S. G. & O~, pages 1321-1326. It should be noted that the prior art only discusses Chitin and certain derivatives thereof which are entirely different than the de-acetylated chitosan employed in the method of this invention and which will be discussed in more detail hereinafter~ The basic structure of natural Chitin is a polymer of N-acetylglucosamine. Although, Balassa describes several molecular modifications and shortenings of chain lengths, Balassa retains the N-acetyl structure on each monomer.
Therefore, it is a principal object of this invention to describe a method of treating a tissue wound so as to achieve hemostasis, to inhibit fibroplasia, and to promote tissue regeneration.
Still another object of the invention is to provide a method of treating a wound whereby chitosan solution, or solid chitosan sheets, powders, or fibers are placed in contact with a tissue wound thereby Eorming a coagulum to prevent ~leeding and to negate the formation of a blood clot to prevent the formation of fibrin strands which in turn prevents the proliferation of fibroblasts and the synthesis of collagen, thus allowing the promotion o~ normal tissue regeneration.
Still another object of the invention is to provide a method of inhibiting fibroplasia and promoting tissue regeneration in vascular grafts by placing chitosan in contact with the graft or by incorporating the chitosan in 3~ the graft material.
- .~;22~26~
Still another object of the invention is to provide a method of achieving hemostasis.
These and other objects will be apparent to those skilled in the art.
This invention consists in the construction, arrangements and combination of the various parts of the device, whereby the objects contemplated are attained as hereinafter more fully set forth, specifically pointed out in the claims, and illustrated in the accompanying drawings, in which:
Figure 1 is a chart which illustrates the results of the chitosan hemostatic solution wound healing evaluation.
As described in Balassa Patent No. 3r804l949r the term "chitin" embraces naturally occuring chitin, synthetic chitin as well as poly (N-acetylgluosamine) and its epimerpoly (N-acetylgalactosamine). Suitable sources of chitin are from lobsters, shrimp, other crustacea and fungi. Chitosan is a derivative of chitin and the method of preparing chitosan is described in U. S. Patent No. 3,533,940 and made a part hereof. Chitosan as used herein refers to a de-acetylated chitosan. Analysis of the chitosan material used herein reveals that most of the acetyls (78-92%) have been removed therefrom leaving a very reactive free amine group (NH2) on the second carbon of most of the g~ucosamine monomers.
The chitosan used in this method is a partially de-acetylated chitin and is a partially depolymerized chitin to form a polyglucosamine chain linked by Beta 1-4 glycosidic bonds with most acetyl groups removed from the number two positions to a 70-92% de-acetylation. Molecular weight determinations may be made hy the method of Wu and Baugh ~Z;~6~
(Journal of Chromatography 128, pages 87-99 (1976)). The degree of de-acetylation of the chitosan may be determined by the method of Hayes and Davies, Proceedings of The First International Conference on Chitin/Chitosan, 1978, pp~ 193-199. Chitosan with defined physical and chemical properties may be prepared from any natural source of arthropod exo-skeletans or fungal cell walls, by controlling the processes of de-acetylation and depolymerization.
The chitosan ernployed in this method may be purchased from Kypro, Inc., 208 Carlson Building, Bellevue, Washington and identified as "CHITOSAN-High Viscosity". The chitosan employed in this method is a mixture of poly~ers with a molecular weight span from 10,000 through 2,055,000, and with individual molecules 78-92~ de-acetylated. In those chitosans tested, the most abundant molecular species have a molecular weights of 1,487,000 to 1,682,000 and a number average of 12~,000 to 322,000 with a dispersity of 5. The product is 78-92% de-acetylated with a mean of 85% de-acetylation. Chitosan in solution, and solid chitosan as fibers, sheets or powders were used.
Although the chitosan employed in the various experiments set forth herein was purchased from Kypro, Inc., the term ~Ichitosan~ is used by several suppllers to denote a product derived by partially de-acetylating chitin. It is with the chitosan purchased from the various sources that the experiments herein began.
The methods of preparing the chitosan so it could be used in the various experiments are described in detail hereinafter with the preferred preparation methods and proportions being described. However, Table A set forth ~Z226g~
hereinbelow lists the characteristics (preferred and permissible) of the chitosan material of this invention.
Chitosans with various sources of origin, states of depolymerization and/or states of de-acetylation were dissolved at a concentration of 2 grams per liter, in distilled water containing the minimum quantity of acetic acid necessary to dissolve the solid material. ~he preferred hemostatic chitosan solution is prepared by dissolving 2 grams of chitosan in 998.5 milliliters of distilled water and 1.5 milliliters of glacial acetic acid. The mixture is stirred at room temperature for 2 to 3 hours to produce a clear chitosan solution in 0.026 N acetic acid having a pH of ~ 0.2. Preferably, the solution is stored at 4C.
Hemostatic chitosan fiber mats were prepared by placing an appropriate quantity of sterile solution in sterile silicone-coated tubes, crystallizing the solution at -60C and ~reeze drying. By varying the diameter of the tubes and placin~
them upright or on their sides in the freezer, the preparation of short dense plugs or long thin strips were obtained. Preferably, 2.5 milliliters of the chitosan solution was utilized to yield 5 milligram mats. Chitosan films were prepared by drying thin layers of solution on flat teflon plate.s without freezing. It has been found that flat fiber mats are easier to handle than films. Chitosan hemostatic powders were prepared by grinding the mats with sterile mortar and pestle. The chitosan hemostatic agent was incorporated into sheets of fabric and tubular grafts by soaking the same in th~ chitosan solution thereby yielding surEace adhesion or by drying the chitosan fibers or amorphous chitosan into the interstices of the fabrics.
12~i98 The chitosan hemostatic solution may be sterilized by filtration through 2-micron filters; however, the process is slow and the yield is low. Steam autoclaving of chitosan solutions produces a marked decrease in coagulum-forming effectiveness. Chitosan acetate and chitosan hydrochloride solutions and lyophilized solids (salts) are heat labile about lOO~C, so chitosan hemostatic solutions, fibers, powders and films should be prepared from sterile chitosan rather than being sterilized after preparation. The best chitosan used in these experiments described herein was heat stable and was sterilized in a steam autoclave at 250F for fifteen minutes~
The inventors herein have discovered that chitosan from shrimp, two species of crab, and two unknown sources ("chitosan practical gradel') formed a hemostatic coagulum when acid solutions of various concentrations were brought into contact with blood in test tubes or in skin incisions in dogs. Chitosan which was only 42~ de-acetylated required up to 1.0 N acid ~or solution (with some solid residue). Poly-glucosamine (100~ de-acetylated chitosan) formed a good coagulum; however, only small quantities were tested. ~ower and medium viscosity chitosans were easily dissolved and quickly sterilized by membrane filters; however, stability of the coagulum was directly proportional to the molecular weight of the most prevalent polymer in the solution. The following experiments were conducted and the experiments support the theory that chitosan prevents fibroplasia and does promote tissue regeneration In the patents of Balassa (3,914,413; 3,911,116; and 3,903,268) rats were treated with chitin derivatives (not 269~3 chitosan), given as solids into the wounds. Prudden's method of tissue tensile strength measurement was used. ~ balloon was introduced into the abdominal cavity of treated and untreated rats at intervals oE five days, seven days and eleven days. The ballons were inflated until the wounds disrupted. The bursting pressure in millimeters of mercury ~as the index of tensile s~rength. The original work of Prudden and Balassa claimed increased tensile strength in cartilage treated rats (over controls) of 20 to ~0~ at five and seven days, but no difference at eleven days. In the Balassa patents, increases of 25% are claimed when chitin is used.
Experiment I
For our first experiment, fifty-four rats were paired by body weight~ One rat's incision was sponged with our chitosan solution (2~0 mg/100 cc in 0.026 N acetic acid) and the other with physiological saline. About one cubic c~ntimeter of viscous chitiosan solution containing 2 milligrams of chitosan stuck to the sides of the abdominal wound. Although we planned nine pairs for each evaluation day, four animals died; leaving eight pairs for da~s 5 and 7, and including one ~Irematched~ pair within 9 g~ams initial weight in the eight pairs for day 11.
The results of the chitosan hemostatic solution wound healing evaluation are depicted in Figure 1. After five days~ we found that six of the eight chitosan treated rats' wounds burst at lower intra-abdominal pressures than their paired control rats. The sum (6 minuses and 2 pluses) of pressure dif~erences between chitosan and control rats was divided by eight to yield a mean bursting pressure decrease :~Z~6g8 of minus 14.4 mm. Hg. This was divided by the mean control bursting pressure to yield an 11~ decrease in the tensile strength of wounds in the chitosan treated rats. At 7 days, five of the eight chitosan treated rats' wounds burst at lower pressures than their paired controls. Computation yielded an insignificant 6.4~ decrease in tensile strength.
At 11 days, five of the chitosan treated rats' wounds burst at slightly higher pressures than the controls. Computation yielded an insignificant 2% decrease in tensile strength.
Experiment II
Our second experiment was an attempt to apply chitosan fiber mats to the standard Prudden abdominal wound. With teflon-coated tweezers, we were able to lay ~ milligrams of matted chitosan fibers along one edge of each standard abdominal wall incisions in female rats. Closing the wounds with suture res~llted in an irregular application of the solid chitosan7 however, some portion of each mat was directly between opposing wound edges. Control animals had nothing added to the wound edges. Evaluation at 5 days revealed that chitosan-treated wounds were grossly deficient in wound healing compared to the controls. In places where the mat had blocked the formation of a blood clot across the wound, wounds broke during insertion of the balloon. When the balloon could be inserted without disrupting the treated wound, the wounds broke irregularly (rather than burst) at much lower pressures than control rats' wounds.
The prior art teaches that N-acetylated partially depolymerized chitin mat~rials facilitate early wound healing by increasing the tensile strength (resistance to disruption) in the early stages of wound healing (5, 7 and 11 days). We ~zçi9~
have found tha~ chitosan hemostatic solution and chitosan hemostatic fiber mats interfere with early wound healing by decreasing the tensile strength in the earliest stage of wound healing (5 days); and that chitosan hemostatic solution has no significant effect on wound healing at later stages (7 and 11 days).
Experiment III
.
It iS well known that porous synthetic vascular grafts, when placed in artery segments, heal by fibrosis. A layer of fibrous tissue and fibrin coat the inside of the structure with another fibrous coating on the outside. The tissue is in effect an avascular scar surrounding a foreign body and as such it does not grow or replenish itself as living tissue would do. It is with this in mind that the experiment was conducted. Porous knitted Dacron~ Debakey grafts were placed in the infrarenal aorta of dogs. Controls were also placed without chitosan solution. The experimental grafts were simply soaked in chitosan hemostatic solution as previously describe~. After 1, 2, 3 and 4 months, bo~h groups o~ grafts were examined grossly and by light and electron microscopy.
The control gra~ts were encased in avascular fibrous tissue.
The chitosan treated grafts were encased in smooth muscle which penetrated the graft interstices. The graft was ; lined with living endothelial cellsr numerous blood vessels (vasa vasovum) supplied this tissue and there was ingrowth of myelinated nerve fibers. In brief, it was found that diverse tissue elements of normal artery regenerated de novo. Thus, these experiments indicated that chitosan when applied to vascular gra~ts results in the inhibition of ~ibroplasia and promotes the regeneration o~ normal tissue elements.
Science has long sought a method to inhibit the synthesis of collagen in wound healing. Much of the work directed to the inhibition of the synthesis of collagen has involved alteration of the biology of collagen by various chemical antagonists. Lower animals do not heal by scar tissue but generate normal structures from pre-existing cells. Usual wound healing begins with a blood clot containing a fibrin network, along which fibroblasts begin the process of fibroplasia~ If blood loss is controlled in the presence of a fibrin clot, fibroblasts will be stimulated. Conversely, if blood loss can be controlled in the absence of a fibrin clot, ~ibroblasts may be not stimulated, and differentiated cells may have the opportunity to replace the lost tissue. It has therefore been found that a material is needed to control blood loss absent the usual blood clot~ing factors, and to allow the ingrowth of normal tissue elements.
Prior art teaches that Chitin and some chitin derivatives accelerate tensile strength of wounds by speeding the fibroblastic synthesis of collagen in the first few days of wound healing. For example, see U. S. Patent Nos.
3,902,268; 3,911,116 and 3,914,413. ThiS topic is also 1~226913 discussed in the May 1970 issue of American Journal of Surgery, pages 560-56~. The subject is further discussed in the June 1969 issue oE S. G. & O~, pages 1321-1326. It should be noted that the prior art only discusses Chitin and certain derivatives thereof which are entirely different than the de-acetylated chitosan employed in the method of this invention and which will be discussed in more detail hereinafter~ The basic structure of natural Chitin is a polymer of N-acetylglucosamine. Although, Balassa describes several molecular modifications and shortenings of chain lengths, Balassa retains the N-acetyl structure on each monomer.
Therefore, it is a principal object of this invention to describe a method of treating a tissue wound so as to achieve hemostasis, to inhibit fibroplasia, and to promote tissue regeneration.
Still another object of the invention is to provide a method of treating a wound whereby chitosan solution, or solid chitosan sheets, powders, or fibers are placed in contact with a tissue wound thereby Eorming a coagulum to prevent ~leeding and to negate the formation of a blood clot to prevent the formation of fibrin strands which in turn prevents the proliferation of fibroblasts and the synthesis of collagen, thus allowing the promotion o~ normal tissue regeneration.
Still another object of the invention is to provide a method of inhibiting fibroplasia and promoting tissue regeneration in vascular grafts by placing chitosan in contact with the graft or by incorporating the chitosan in 3~ the graft material.
- .~;22~26~
Still another object of the invention is to provide a method of achieving hemostasis.
These and other objects will be apparent to those skilled in the art.
This invention consists in the construction, arrangements and combination of the various parts of the device, whereby the objects contemplated are attained as hereinafter more fully set forth, specifically pointed out in the claims, and illustrated in the accompanying drawings, in which:
Figure 1 is a chart which illustrates the results of the chitosan hemostatic solution wound healing evaluation.
As described in Balassa Patent No. 3r804l949r the term "chitin" embraces naturally occuring chitin, synthetic chitin as well as poly (N-acetylgluosamine) and its epimerpoly (N-acetylgalactosamine). Suitable sources of chitin are from lobsters, shrimp, other crustacea and fungi. Chitosan is a derivative of chitin and the method of preparing chitosan is described in U. S. Patent No. 3,533,940 and made a part hereof. Chitosan as used herein refers to a de-acetylated chitosan. Analysis of the chitosan material used herein reveals that most of the acetyls (78-92%) have been removed therefrom leaving a very reactive free amine group (NH2) on the second carbon of most of the g~ucosamine monomers.
The chitosan used in this method is a partially de-acetylated chitin and is a partially depolymerized chitin to form a polyglucosamine chain linked by Beta 1-4 glycosidic bonds with most acetyl groups removed from the number two positions to a 70-92% de-acetylation. Molecular weight determinations may be made hy the method of Wu and Baugh ~Z;~6~
(Journal of Chromatography 128, pages 87-99 (1976)). The degree of de-acetylation of the chitosan may be determined by the method of Hayes and Davies, Proceedings of The First International Conference on Chitin/Chitosan, 1978, pp~ 193-199. Chitosan with defined physical and chemical properties may be prepared from any natural source of arthropod exo-skeletans or fungal cell walls, by controlling the processes of de-acetylation and depolymerization.
The chitosan ernployed in this method may be purchased from Kypro, Inc., 208 Carlson Building, Bellevue, Washington and identified as "CHITOSAN-High Viscosity". The chitosan employed in this method is a mixture of poly~ers with a molecular weight span from 10,000 through 2,055,000, and with individual molecules 78-92~ de-acetylated. In those chitosans tested, the most abundant molecular species have a molecular weights of 1,487,000 to 1,682,000 and a number average of 12~,000 to 322,000 with a dispersity of 5. The product is 78-92% de-acetylated with a mean of 85% de-acetylation. Chitosan in solution, and solid chitosan as fibers, sheets or powders were used.
Although the chitosan employed in the various experiments set forth herein was purchased from Kypro, Inc., the term ~Ichitosan~ is used by several suppllers to denote a product derived by partially de-acetylating chitin. It is with the chitosan purchased from the various sources that the experiments herein began.
The methods of preparing the chitosan so it could be used in the various experiments are described in detail hereinafter with the preferred preparation methods and proportions being described. However, Table A set forth ~Z226g~
hereinbelow lists the characteristics (preferred and permissible) of the chitosan material of this invention.
Chitosans with various sources of origin, states of depolymerization and/or states of de-acetylation were dissolved at a concentration of 2 grams per liter, in distilled water containing the minimum quantity of acetic acid necessary to dissolve the solid material. ~he preferred hemostatic chitosan solution is prepared by dissolving 2 grams of chitosan in 998.5 milliliters of distilled water and 1.5 milliliters of glacial acetic acid. The mixture is stirred at room temperature for 2 to 3 hours to produce a clear chitosan solution in 0.026 N acetic acid having a pH of ~ 0.2. Preferably, the solution is stored at 4C.
Hemostatic chitosan fiber mats were prepared by placing an appropriate quantity of sterile solution in sterile silicone-coated tubes, crystallizing the solution at -60C and ~reeze drying. By varying the diameter of the tubes and placin~
them upright or on their sides in the freezer, the preparation of short dense plugs or long thin strips were obtained. Preferably, 2.5 milliliters of the chitosan solution was utilized to yield 5 milligram mats. Chitosan films were prepared by drying thin layers of solution on flat teflon plate.s without freezing. It has been found that flat fiber mats are easier to handle than films. Chitosan hemostatic powders were prepared by grinding the mats with sterile mortar and pestle. The chitosan hemostatic agent was incorporated into sheets of fabric and tubular grafts by soaking the same in th~ chitosan solution thereby yielding surEace adhesion or by drying the chitosan fibers or amorphous chitosan into the interstices of the fabrics.
12~i98 The chitosan hemostatic solution may be sterilized by filtration through 2-micron filters; however, the process is slow and the yield is low. Steam autoclaving of chitosan solutions produces a marked decrease in coagulum-forming effectiveness. Chitosan acetate and chitosan hydrochloride solutions and lyophilized solids (salts) are heat labile about lOO~C, so chitosan hemostatic solutions, fibers, powders and films should be prepared from sterile chitosan rather than being sterilized after preparation. The best chitosan used in these experiments described herein was heat stable and was sterilized in a steam autoclave at 250F for fifteen minutes~
The inventors herein have discovered that chitosan from shrimp, two species of crab, and two unknown sources ("chitosan practical gradel') formed a hemostatic coagulum when acid solutions of various concentrations were brought into contact with blood in test tubes or in skin incisions in dogs. Chitosan which was only 42~ de-acetylated required up to 1.0 N acid ~or solution (with some solid residue). Poly-glucosamine (100~ de-acetylated chitosan) formed a good coagulum; however, only small quantities were tested. ~ower and medium viscosity chitosans were easily dissolved and quickly sterilized by membrane filters; however, stability of the coagulum was directly proportional to the molecular weight of the most prevalent polymer in the solution. The following experiments were conducted and the experiments support the theory that chitosan prevents fibroplasia and does promote tissue regeneration In the patents of Balassa (3,914,413; 3,911,116; and 3,903,268) rats were treated with chitin derivatives (not 269~3 chitosan), given as solids into the wounds. Prudden's method of tissue tensile strength measurement was used. ~ balloon was introduced into the abdominal cavity of treated and untreated rats at intervals oE five days, seven days and eleven days. The ballons were inflated until the wounds disrupted. The bursting pressure in millimeters of mercury ~as the index of tensile s~rength. The original work of Prudden and Balassa claimed increased tensile strength in cartilage treated rats (over controls) of 20 to ~0~ at five and seven days, but no difference at eleven days. In the Balassa patents, increases of 25% are claimed when chitin is used.
Experiment I
For our first experiment, fifty-four rats were paired by body weight~ One rat's incision was sponged with our chitosan solution (2~0 mg/100 cc in 0.026 N acetic acid) and the other with physiological saline. About one cubic c~ntimeter of viscous chitiosan solution containing 2 milligrams of chitosan stuck to the sides of the abdominal wound. Although we planned nine pairs for each evaluation day, four animals died; leaving eight pairs for da~s 5 and 7, and including one ~Irematched~ pair within 9 g~ams initial weight in the eight pairs for day 11.
The results of the chitosan hemostatic solution wound healing evaluation are depicted in Figure 1. After five days~ we found that six of the eight chitosan treated rats' wounds burst at lower intra-abdominal pressures than their paired control rats. The sum (6 minuses and 2 pluses) of pressure dif~erences between chitosan and control rats was divided by eight to yield a mean bursting pressure decrease :~Z~6g8 of minus 14.4 mm. Hg. This was divided by the mean control bursting pressure to yield an 11~ decrease in the tensile strength of wounds in the chitosan treated rats. At 7 days, five of the eight chitosan treated rats' wounds burst at lower pressures than their paired controls. Computation yielded an insignificant 6.4~ decrease in tensile strength.
At 11 days, five of the chitosan treated rats' wounds burst at slightly higher pressures than the controls. Computation yielded an insignificant 2% decrease in tensile strength.
Experiment II
Our second experiment was an attempt to apply chitosan fiber mats to the standard Prudden abdominal wound. With teflon-coated tweezers, we were able to lay ~ milligrams of matted chitosan fibers along one edge of each standard abdominal wall incisions in female rats. Closing the wounds with suture res~llted in an irregular application of the solid chitosan7 however, some portion of each mat was directly between opposing wound edges. Control animals had nothing added to the wound edges. Evaluation at 5 days revealed that chitosan-treated wounds were grossly deficient in wound healing compared to the controls. In places where the mat had blocked the formation of a blood clot across the wound, wounds broke during insertion of the balloon. When the balloon could be inserted without disrupting the treated wound, the wounds broke irregularly (rather than burst) at much lower pressures than control rats' wounds.
The prior art teaches that N-acetylated partially depolymerized chitin mat~rials facilitate early wound healing by increasing the tensile strength (resistance to disruption) in the early stages of wound healing (5, 7 and 11 days). We ~zçi9~
have found tha~ chitosan hemostatic solution and chitosan hemostatic fiber mats interfere with early wound healing by decreasing the tensile strength in the earliest stage of wound healing (5 days); and that chitosan hemostatic solution has no significant effect on wound healing at later stages (7 and 11 days).
Experiment III
.
It iS well known that porous synthetic vascular grafts, when placed in artery segments, heal by fibrosis. A layer of fibrous tissue and fibrin coat the inside of the structure with another fibrous coating on the outside. The tissue is in effect an avascular scar surrounding a foreign body and as such it does not grow or replenish itself as living tissue would do. It is with this in mind that the experiment was conducted. Porous knitted Dacron~ Debakey grafts were placed in the infrarenal aorta of dogs. Controls were also placed without chitosan solution. The experimental grafts were simply soaked in chitosan hemostatic solution as previously describe~. After 1, 2, 3 and 4 months, bo~h groups o~ grafts were examined grossly and by light and electron microscopy.
The control gra~ts were encased in avascular fibrous tissue.
The chitosan treated grafts were encased in smooth muscle which penetrated the graft interstices. The graft was ; lined with living endothelial cellsr numerous blood vessels (vasa vasovum) supplied this tissue and there was ingrowth of myelinated nerve fibers. In brief, it was found that diverse tissue elements of normal artery regenerated de novo. Thus, these experiments indicated that chitosan when applied to vascular gra~ts results in the inhibition of ~ibroplasia and promotes the regeneration o~ normal tissue elements.
2~
Dogs that were completely anticoagulated (blood clotting times greater than one hour) by sodium heparin in~ection prior to the operation showed no leakage of blood through the porous graft. Regeneration of a smooth muscle wall around the graft was observed at 1, 2, 3 and 4 months.
Experiment IV
Skin wounds 2 cm. long were mad~ in the abdominal skin penetrating through the subcutaneous tissue in five healthy mongrel dogs. Each dog received four wounds. One wound was treated only with a saline compress, one with a standard hemostatic agent (gelatin foam), one with the described chitosan solution and one with chitosan solu~ion fiber mats.
The wounds were examined immediately and at intervals of 24 hours, 72 hours, seven days and at one month. Gross examination and light microscopy were done. The saline control wound resulted in the usual broad scar. The wound with the hemostatic agent revealed that the gelatin foam remained in the wound with severe tissue reaction. Solid chitosan revealed a scar similar to that of gelatin oam.
The wounds treated with chitosan solution healed with thin scars.
Experiment V
-Incised wounds 2 cm. long and 1 cm. deep were made in ~he left rectus abdominus muscle of ~ive healthy mongrel dogs. As in Example IV, the wounds were treated with saline compress, hemostatic agent, chitosan solution, and chitosan fiber mats. The examination intervals were immediate, 24 hours, 72 hours, seven days and 30 days. Gross examination and light microscopy were utilized to determine the amount oE scar tissue present. Since muscle retracts ~L~Z2216~
when cut, the tissue defect was quite wide. The saline treated muscle wound resulted in a ~ide scar. The wound treated with the standard hemostatic agent revealed severe tissue reaction with remnants of the gelatin foam still present at one month. The wounds treated with chitosan solution and lyophylized chitosan revealed less scar tissue and muscle proliferation.
Experiment _ Incised wounds 2 cm. long and 1 cm. deep were made in the liver of five healthy mongrel dogs. The wounds were treated with a standard hemostatic agent, chitosan solution, and lyophylized chitosan. The wounds were examined at intervals grossly and with light microscopy. The wound treated with the hemostatic agent revealed severe scarring and the hemostatic material was still in the wound at one month. The wounds treated with chitosan solution and lyophylized chitosan revealed smaller scars and some regeneration of hepatic tissue.
Experiment VII
Incised wounds 2 cm. long and 1 cm. deep were made in the spleen of five healthy mongrel dog5. These wounds were treated with the standard hemostatic agent, the described chitosan solution and the lyophylized chitosan. Examination of the wounds at intervals grossly and by light microscopy revealed that the wound treated with the standard hemostatic agent contained severe tissue reaction with scarring and retained hemostatic agent. The wounds treated with chitosan solution and lyophylized chitosan revealed practically no tissue reaction and small s~ars.
1~;269~
Experiment V _ Identical avulsions (scoop wounds) were made in the right and left parietal lobes of the brains of mongrel cats.
The chitosan hemostatic solution of this invention was as effective in achieving hemostasis as other liquid (thrombin solution) and solid hemostatic agents. At the end of one month, the chitosan wounds in which hemostasis was best showed less fibrous scar, fewer pigment-laden macrophages, and a greater number of glial elements.
Experiment IX
The chitosan hemostatic solution of this invention was applied to exposed bone marrow surfaces in the hips of dogs and the solution stopped the blood from oozing over the surface. At one week, the control sites were covered by an organized thick blood clot containing many macrophages and fibroblasts. The chitosan treated surfaces were coated by a thin coagulum containing fewer macrophages and fibroblasts.
The chitosan solution was also injected into the traumatized hip joint of a mongrel dog. At one week, there were fewer blood and inflammatory cells in the joint fluid than in the 0.026 N acetic acid control joint.
The foregoing experiments reveal that chitosan whether in solution in pH 4 acetic acid, fiber mats, or powders, inhibits fibroplasia, and promotes tissue regeneration while achieving hemostasis.
Table A hereinbelow lists the various characteristics of the chitosan solution to enable the desired hemostasis, inhibition of fibroplasia and promotion oP tissue regeneration to be achieved.
TABLE A
Characteristic Preferred Permissible __ Source Dungness crabs ~rthropods or Fungi Deacetylation 85% 42 to 100%
Molecular Weight Range 10,000 to 10,000 to 2,055,000 2,055,000 Molecular Weight of 1,600,000 900,000 to Most Abundant Species 1,800,000 Concentration 2 grams per liter 0.5 to 8 grams per liter pH 4 1 to 8 Solute Concentration ~Iypotonic Hypotonic to Hypertonic@
Acid Acetic Hydrochloric sulphuric, phosphoric, organic Acid Concentration 0.026 N 0.02 to 1.0 Permissible ranges are not independently variable. Chitosans of high molecular weight and lower deacetylation will require higher acid concentrations just to put the material into solution.
@ compared to normal blood solute concentration.
The conclusions to be reached by studying Experiments I-IX hereinabove are that the chitosan of this invention does achieve hemostasis, does inhibit fibroplasia and does promote tissue regeneration.
Dogs that were completely anticoagulated (blood clotting times greater than one hour) by sodium heparin in~ection prior to the operation showed no leakage of blood through the porous graft. Regeneration of a smooth muscle wall around the graft was observed at 1, 2, 3 and 4 months.
Experiment IV
Skin wounds 2 cm. long were mad~ in the abdominal skin penetrating through the subcutaneous tissue in five healthy mongrel dogs. Each dog received four wounds. One wound was treated only with a saline compress, one with a standard hemostatic agent (gelatin foam), one with the described chitosan solution and one with chitosan solu~ion fiber mats.
The wounds were examined immediately and at intervals of 24 hours, 72 hours, seven days and at one month. Gross examination and light microscopy were done. The saline control wound resulted in the usual broad scar. The wound with the hemostatic agent revealed that the gelatin foam remained in the wound with severe tissue reaction. Solid chitosan revealed a scar similar to that of gelatin oam.
The wounds treated with chitosan solution healed with thin scars.
Experiment V
-Incised wounds 2 cm. long and 1 cm. deep were made in ~he left rectus abdominus muscle of ~ive healthy mongrel dogs. As in Example IV, the wounds were treated with saline compress, hemostatic agent, chitosan solution, and chitosan fiber mats. The examination intervals were immediate, 24 hours, 72 hours, seven days and 30 days. Gross examination and light microscopy were utilized to determine the amount oE scar tissue present. Since muscle retracts ~L~Z2216~
when cut, the tissue defect was quite wide. The saline treated muscle wound resulted in a ~ide scar. The wound treated with the standard hemostatic agent revealed severe tissue reaction with remnants of the gelatin foam still present at one month. The wounds treated with chitosan solution and lyophylized chitosan revealed less scar tissue and muscle proliferation.
Experiment _ Incised wounds 2 cm. long and 1 cm. deep were made in the liver of five healthy mongrel dogs. The wounds were treated with a standard hemostatic agent, chitosan solution, and lyophylized chitosan. The wounds were examined at intervals grossly and with light microscopy. The wound treated with the hemostatic agent revealed severe scarring and the hemostatic material was still in the wound at one month. The wounds treated with chitosan solution and lyophylized chitosan revealed smaller scars and some regeneration of hepatic tissue.
Experiment VII
Incised wounds 2 cm. long and 1 cm. deep were made in the spleen of five healthy mongrel dog5. These wounds were treated with the standard hemostatic agent, the described chitosan solution and the lyophylized chitosan. Examination of the wounds at intervals grossly and by light microscopy revealed that the wound treated with the standard hemostatic agent contained severe tissue reaction with scarring and retained hemostatic agent. The wounds treated with chitosan solution and lyophylized chitosan revealed practically no tissue reaction and small s~ars.
1~;269~
Experiment V _ Identical avulsions (scoop wounds) were made in the right and left parietal lobes of the brains of mongrel cats.
The chitosan hemostatic solution of this invention was as effective in achieving hemostasis as other liquid (thrombin solution) and solid hemostatic agents. At the end of one month, the chitosan wounds in which hemostasis was best showed less fibrous scar, fewer pigment-laden macrophages, and a greater number of glial elements.
Experiment IX
The chitosan hemostatic solution of this invention was applied to exposed bone marrow surfaces in the hips of dogs and the solution stopped the blood from oozing over the surface. At one week, the control sites were covered by an organized thick blood clot containing many macrophages and fibroblasts. The chitosan treated surfaces were coated by a thin coagulum containing fewer macrophages and fibroblasts.
The chitosan solution was also injected into the traumatized hip joint of a mongrel dog. At one week, there were fewer blood and inflammatory cells in the joint fluid than in the 0.026 N acetic acid control joint.
The foregoing experiments reveal that chitosan whether in solution in pH 4 acetic acid, fiber mats, or powders, inhibits fibroplasia, and promotes tissue regeneration while achieving hemostasis.
Table A hereinbelow lists the various characteristics of the chitosan solution to enable the desired hemostasis, inhibition of fibroplasia and promotion oP tissue regeneration to be achieved.
TABLE A
Characteristic Preferred Permissible __ Source Dungness crabs ~rthropods or Fungi Deacetylation 85% 42 to 100%
Molecular Weight Range 10,000 to 10,000 to 2,055,000 2,055,000 Molecular Weight of 1,600,000 900,000 to Most Abundant Species 1,800,000 Concentration 2 grams per liter 0.5 to 8 grams per liter pH 4 1 to 8 Solute Concentration ~Iypotonic Hypotonic to Hypertonic@
Acid Acetic Hydrochloric sulphuric, phosphoric, organic Acid Concentration 0.026 N 0.02 to 1.0 Permissible ranges are not independently variable. Chitosans of high molecular weight and lower deacetylation will require higher acid concentrations just to put the material into solution.
@ compared to normal blood solute concentration.
The conclusions to be reached by studying Experiments I-IX hereinabove are that the chitosan of this invention does achieve hemostasis, does inhibit fibroplasia and does promote tissue regeneration.
Claims (10)
1. A pharmaceutical composition for achieving hemostasis, inhibiting fibroplasia and promoting tissue regeneration comprising chitosan together with a pharmaceutically acceptable carrier, said chitosan being 78-92% de-acetylated chitin.
2. A composition as claimed in claim 1 wherein said chitosan has a molecular weight of 10,000 to 2,055,000.
3. A composition as claimed in claim 1 or 2 wherein the chitosan is in solution with distilled water and acetic acid and has a pH of approximately 4.
4. A composition as claimed in claim 1 or 2 wherein said chitosan is in solid form.
5. A composition as claimed in claim 1 wherein said chitosan is in solid form and is a salt prepared by dehydrating an acid solution of chitosan.
6. A composition as claimed in claim 2 wherein said chitosan is in solid form and is a salt prepared by dehydrating an acid solution of chitosan.
7. A composition as claimed in claim 5 wherein said chitosan comprises a powder, a film, a sheet or is in fiber form.
8. A composition as claimed in claim 6 wherein said chitosan comprises a powder, a film, a sheet or is in fiber form.
9. A composition as claimed in claim 5 wherein said chitosan fibers are formed into mats or plugs.
10. A composition as claimed in claim 6 wherein said chitosan fibers are formed into mats or plugs.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US06/440,039 US4532134A (en) | 1981-04-06 | 1982-11-08 | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
US440,039 | 1989-11-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CA1222698A true CA1222698A (en) | 1987-06-09 |
Family
ID=23747168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA000430203A Expired CA1222698A (en) | 1982-11-08 | 1983-06-10 | Method of achieving hemostasis, inhibiting fibroplasia, and promoting regeneration in a tissue wound |
Country Status (5)
Country | Link |
---|---|
US (1) | US4532134A (en) |
JP (1) | JPS5988424A (en) |
CA (1) | CA1222698A (en) |
DE (1) | DE3321446C2 (en) |
GB (1) | GB2129300B (en) |
Families Citing this family (118)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4452785A (en) * | 1982-11-08 | 1984-06-05 | Malette William Graham | Method for the therapeutic occlusion |
JPS6129720U (en) * | 1984-07-28 | 1986-02-22 | 高砂医科工業株式会社 | Intestinal anastomosis aid |
US4960413A (en) * | 1985-11-09 | 1990-10-02 | The Shirley Institute | Wound dressing |
JP2527317B2 (en) * | 1986-12-19 | 1996-08-21 | ライオン株式会社 | Bone disease treatment |
US4873092A (en) * | 1987-05-21 | 1989-10-10 | Murata Kikai Kabushiki Kaisha | Slow-releasing preparation |
US4900553A (en) * | 1987-09-11 | 1990-02-13 | Case Western Reserve University | Method of reducing glial scar formation and promoting axon and blood vessel growth and/or regeneration through the use of activated immature astrocytes |
US5180426A (en) * | 1987-12-28 | 1993-01-19 | Asahi Kogaku Kogyo K.K. | Composition for forming calcium phosphate type setting material and process for producing setting material |
US4952618A (en) * | 1988-05-03 | 1990-08-28 | Minnesota Mining And Manufacturing Company | Hydrocolloid/adhesive composition |
JP2798287B2 (en) * | 1989-02-08 | 1998-09-17 | ユニチカ株式会社 | Anti-inflammatory agent |
US5093319A (en) * | 1989-10-31 | 1992-03-03 | Pfizer Hospital Products Group, Inc. | Use of derivatives of chitin soluble in aqueous solutions for preventing adhesions |
US4994277A (en) * | 1989-10-31 | 1991-02-19 | Pfizer Hospital Products Group, Inc. | Use of xanthan gum for preventing adhesions |
JP2579610B2 (en) * | 1990-09-28 | 1997-02-05 | 鳥取大学長 | In vivo filler |
JP2714621B2 (en) * | 1991-05-31 | 1998-02-16 | サンファイブ 株式会社 | Wound healing agent |
DE4200080A1 (en) * | 1992-01-03 | 1993-09-30 | Reinmueller Johannes | Pharmaceutical composition for wound, scar and keloid treatment |
CA2114290C (en) * | 1993-01-27 | 2006-01-10 | Nagabushanam Totakura | Post-surgical anti-adhesion device |
DE4322956C2 (en) * | 1993-07-09 | 1995-12-21 | Haack Karl Werner An | Chitosan film for wound sealing |
US6743783B1 (en) * | 1993-12-01 | 2004-06-01 | Marine Polymer Technologies, Inc. | Pharmaceutical compositions comprising poly-β-1→4-N-acetylglucosamine |
US5858350A (en) | 1993-12-01 | 1999-01-12 | Marine Polymer Technologies | Methods and compositions for poly-β-1→4-N-acetylglucosamine cell therapy system |
US5846952A (en) * | 1993-12-01 | 1998-12-08 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine drug delivery |
US5622834A (en) * | 1993-12-01 | 1997-04-22 | Marine Polymer Technologies, Inc. | Method of isolating poly-β-1-4-N-acetylglucosamine from microalgal culture |
US5635493A (en) * | 1993-12-01 | 1997-06-03 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics |
US5624679A (en) * | 1993-12-01 | 1997-04-29 | Marine Polymer Technologies, Inc. | Methods and compositions for poly-β-1-4-N-acetylglucosamine biological barriers |
US5686115A (en) * | 1993-12-01 | 1997-11-11 | Marine Polymer Technologies, Inc. | Poly-β-1→4-N-acetylucosamine copolymer composition with collagen |
SE9402531L (en) * | 1994-07-19 | 1996-01-20 | Medicarb Ab | wound healing agent |
US5607686A (en) * | 1994-11-22 | 1997-03-04 | United States Surgical Corporation | Polymeric composition |
US5612052A (en) * | 1995-04-13 | 1997-03-18 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6551610B2 (en) | 1995-04-13 | 2003-04-22 | Poly-Med, Inc. | Multifaceted compositions for post-surgical adhesion prevention |
US6413539B1 (en) | 1996-10-31 | 2002-07-02 | Poly-Med, Inc. | Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof |
US6150581A (en) * | 1995-06-07 | 2000-11-21 | United States Surgical Corporation | Chitosan/alginate anti-adhesion barrier |
US5810846A (en) * | 1995-08-03 | 1998-09-22 | United States Surgical Corporation | Vascular hole closure |
US5674231A (en) * | 1995-10-20 | 1997-10-07 | United States Surgical Corporation | Apparatus and method for vascular hole closure |
US5733884A (en) * | 1995-11-07 | 1998-03-31 | Nestec Ltd. | Enteral formulation designed for optimized wound healing |
SE9600216D0 (en) * | 1996-01-18 | 1996-01-18 | Hans Arne Hansson | Control of healing processes |
DE19724869C2 (en) * | 1997-06-12 | 1999-05-12 | Henkel Kgaa | Use of citosan derivatives for surface coating |
US6162241A (en) * | 1997-08-06 | 2000-12-19 | Focal, Inc. | Hemostatic tissue sealants |
US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
US6632457B1 (en) * | 1998-08-14 | 2003-10-14 | Incept Llc | Composite hydrogel drug delivery systems |
US6514534B1 (en) | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
ES2491866T3 (en) * | 1999-11-15 | 2014-09-08 | Piramal Healthcare (Canada) Limited | Temperature-controlled, pH-dependent, self-gelling aqueous biopolymer solution |
GB9929472D0 (en) * | 1999-12-13 | 2000-02-09 | Btg Int Ltd | Polymeric film |
WO2001054748A1 (en) * | 2000-01-25 | 2001-08-02 | Edwards Lifesciences Corporation | Delivery systems for treatment of restenosis and anastomotic intimal hyperplasia |
ATE480186T1 (en) * | 2000-02-24 | 2010-09-15 | Univ Loma Linda Med | PLASTER AND ADHESIVE DELIVERY SYSTEM FOR CLOSING A TISSUE OPENING DURING SURGICAL TREATMENT |
DK1294414T3 (en) * | 2000-06-29 | 2006-07-24 | Biosyntech Canada Inc | Preparation and method of healing and regenerating cartilage and other tissues |
US6890342B2 (en) | 2000-08-02 | 2005-05-10 | Loma Linda University | Method and apparatus for closing vascular puncture using hemostatic material |
US20040091540A1 (en) * | 2000-11-15 | 2004-05-13 | Desrosiers Eric Andre | Method for restoring a damaged or degenerated intervertebral disc |
KR100953466B1 (en) | 2001-06-14 | 2010-04-16 | 프로비던스 헬스 시스템-오레곤 | A method for preparing a wound dressing useful for secere, life-threatening bleeding |
US20050147656A1 (en) * | 2001-06-14 | 2005-07-07 | Hemcon, Inc. | Tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
US20060004314A1 (en) * | 2001-06-14 | 2006-01-05 | Hemcon, Inc. | Antimicrobial barriers, systems, and methods formed from hydrophilic polymer structures such as chistosan |
US8741335B2 (en) | 2002-06-14 | 2014-06-03 | Hemcon Medical Technologies, Inc. | Hemostatic compositions, assemblies, systems, and methods employing particulate hemostatic agents formed from hydrophilic polymer foam such as Chitosan |
US7371403B2 (en) * | 2002-06-14 | 2008-05-13 | Providence Health System-Oregon | Wound dressing and method for controlling severe, life-threatening bleeding |
US7897832B2 (en) * | 2001-06-14 | 2011-03-01 | Hemcon Medical Technologies, Inc. | Compositions, assemblies, and methods applied during or after a dental procedure to ameliorate fluid loss and/or promote healing, using a hydrophilic polymer sponge structure such as chitosan |
IS6085A (en) * | 2001-09-26 | 2003-03-27 | Genis Ehf. | Medication with chitosan oligomers |
US20030093114A1 (en) * | 2001-11-13 | 2003-05-15 | Melvin Levinson | Method for effecting hemostasis |
US20050070500A1 (en) * | 2001-12-13 | 2005-03-31 | Boucher L Isabelle | Method of modulating release of saccharides and uses thereof |
US20050004057A1 (en) * | 2001-12-14 | 2005-01-06 | Isabelle Boucher | Chitosan oligosaccharides and uses thereof |
ATE342000T1 (en) * | 2002-06-14 | 2006-11-15 | Univ Loma Linda Med | DEVICE FOR CLOSING VASCULAR WOUNDS |
US20050137512A1 (en) * | 2003-12-23 | 2005-06-23 | Campbell Todd D. | Wound dressing and method for controlling severe, life-threatening bleeding |
US8269058B2 (en) * | 2002-06-14 | 2012-09-18 | Hemcon Medical Technologies, Inc. | Absorbable tissue dressing assemblies, systems, and methods formed from hydrophilic polymer sponge structures such as chitosan |
CN1835723B (en) * | 2003-06-16 | 2011-06-22 | 洛马林达大学医学中心 | Deployable multifunctional hemostatic agent |
US8012167B2 (en) * | 2003-08-14 | 2011-09-06 | Loma Linda University Medical Center | Vascular wound closure device and method |
US8187627B2 (en) | 2003-09-05 | 2012-05-29 | Loma Linda University Medical Center | Dressing delivery system for internal wounds |
EP1701751B1 (en) * | 2003-11-14 | 2011-12-21 | Interventional Therapies, LLC | Improved ferrule |
SE0303588D0 (en) * | 2003-12-30 | 2003-12-30 | Bioactive Polymers Ab C O Lund | Surface protection of exposed biological tissues |
DE102004007115A1 (en) * | 2004-02-13 | 2005-08-25 | Cognis Deutschland Gmbh & Co. Kg | Chitosan-containing wound dressings |
US8703176B2 (en) * | 2004-02-23 | 2014-04-22 | Loma Linda University Medical Center | Hemostatic agent for topical and internal use |
WO2005087280A1 (en) * | 2004-03-11 | 2005-09-22 | Medtrade Products Limited | Compositions of alpha and beta chitosan and methods of preparing them |
US20050283004A1 (en) * | 2004-06-18 | 2005-12-22 | Hopax Chemicals Manufacturing Co., Ltd. | Alkylsulfonated polyaminosaccharides |
US9204957B2 (en) * | 2005-03-17 | 2015-12-08 | Hemcon Medical Technologies, Inc. | Systems and methods for hemorrhage control and or tissue repair |
US20070031468A1 (en) * | 2005-08-04 | 2007-02-08 | Endomedix, Inc. | Modified chitosan for vascular embolization |
US20070031467A1 (en) * | 2005-08-04 | 2007-02-08 | Abrahams John M | Composition and method for vascular embolization |
ATE499882T1 (en) | 2005-10-05 | 2011-03-15 | Univ Loma Linda Med | VESSEL WOUND CLOSURE DEVICE |
GB0526505D0 (en) | 2005-12-29 | 2006-02-08 | Medtrade Products Ltd | Hemostatic material |
US20070243130A1 (en) * | 2006-04-18 | 2007-10-18 | Weiliam Chen | Biopolymer system for tissue sealing |
US7854923B2 (en) | 2006-04-18 | 2010-12-21 | Endomedix, Inc. | Biopolymer system for tissue sealing |
US20080075657A1 (en) * | 2006-04-18 | 2008-03-27 | Abrahams John M | Biopolymer system for tissue sealing |
EP2010238A2 (en) * | 2006-04-20 | 2009-01-07 | Vivolution A/S | Improved fibrin sealant composition and its use |
EP2026850B1 (en) | 2006-05-23 | 2014-07-09 | Providence Health System-Oregon d/b/a Providence St. Vincent Medical Center | Systems and methods for introducing and applying a bandage structure within a body lumen or hollow body organ |
CA2653390C (en) | 2006-06-02 | 2014-07-08 | Hawaii Chitopure, Inc. | Chitosan-derivative compounds and methods of controlling microbial populations |
US20080124395A1 (en) * | 2006-06-22 | 2008-05-29 | Weiliam Chen | Formulations and devices for treatment or prevention of neural ischemic damage |
US20080248508A1 (en) * | 2006-08-17 | 2008-10-09 | Shenda Baker | Methods of making a chitosan product having an ultra-low endotoxin concentration and the ultra-low endotoxin chitosan product derived therefrom and method of accurately determining inflammatory and anti-inflammatory cellular response to such materials |
CA2672936A1 (en) * | 2006-11-30 | 2008-06-05 | Bio Syntech Canada Inc. | Method for in situ solidification of blood-polymer compositions for regenerative medicine and cartilage repair applications |
NZ616957A (en) | 2007-02-19 | 2015-06-26 | Marinepolymer Tech Inc | Hemostatic compositions and therapeutic regimens |
US9066885B2 (en) * | 2007-03-16 | 2015-06-30 | University Of Maryland, College Park | Advanced functional biocompatible polymeric matrix containing nano-compartments |
US8932560B2 (en) * | 2007-09-04 | 2015-01-13 | University of Maryland, College Parke | Advanced functional biocompatible polymeric matrix used as a hemostatic agent and system for damaged tissues and cells |
EP2095832A1 (en) | 2008-02-28 | 2009-09-02 | Bayer MaterialScience AG | Post-operative adhesion barriers |
GB2461019B (en) | 2008-04-25 | 2013-06-05 | Medtrade Products Ltd | Haemostatic material |
CA2723172A1 (en) * | 2008-05-02 | 2009-11-05 | Providence Health System-Oregon D/B/A Providence St. Vincent Medical Cen Ter | Wound dressing devices and methods |
US20110274726A1 (en) | 2008-10-06 | 2011-11-10 | Providence Health System - Oregon | Chitosan foam medical devices and methods |
EP2396070A4 (en) * | 2009-02-12 | 2012-09-19 | Incept Llc | Drug delivery through hydrogel plugs |
WO2011026498A1 (en) | 2009-09-01 | 2011-03-10 | Medovent Gmbh | Chitosan tissue dressing |
CN102695500A (en) * | 2009-11-09 | 2012-09-26 | 聚光灯技术合伙有限责任公司 | Polysaccharide based hydrogels |
JP2013509963A (en) | 2009-11-09 | 2013-03-21 | スポットライト テクノロジー パートナーズ エルエルシー | Fragmented hydrogel |
CA2780898A1 (en) | 2009-11-13 | 2011-05-19 | University Of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
WO2011066471A1 (en) | 2009-11-25 | 2011-06-03 | Loma Linda University Medical Center | Chitosan-based hemostatic textile |
CA2795520C (en) | 2010-04-06 | 2018-03-06 | Synedgen Inc. | Methods and compositions for treating wounds utilizing chitosan compounds |
JP2013523898A (en) | 2010-04-15 | 2013-06-17 | マリン ポリマー テクノロジーズ,インコーポレーテッド | Antibacterial application of poly-N-acetylglucosamine nanofibers |
EP2603246B1 (en) | 2010-08-13 | 2019-04-03 | University of Maryland, College Park | Method and system for reversal of interactions between hydrophobically modified biopolymers and vesicles or cell membranes |
US11311644B2 (en) * | 2010-09-01 | 2022-04-26 | Medoderm Gmbh | Antimicrobial and/or epithelial cell growth stimulating substance and composition and tissue dressing material |
US8858883B2 (en) | 2010-12-02 | 2014-10-14 | University Of Maryland, College Park | Method and system for capture and use of intact vesicles on electrodeposited hydrophobically modified biopolymer films |
CN107362171A (en) | 2011-04-15 | 2017-11-21 | 海洋聚合物技术公司 | Disease is treated with poly- N acetyl glucosamines nanofiber |
EP2612846A1 (en) | 2012-01-09 | 2013-07-10 | Bayer MaterialScience AG | Beta amino acid esters and use of same |
EP2897622B1 (en) | 2012-09-20 | 2021-04-21 | Synedgen, Inc. | Methods for treatment or prevention of damage resulting from radiation |
CN103007334B (en) * | 2012-12-24 | 2014-11-19 | 南通大学 | Liquid wound repairing film and preparation method thereof |
CA2914610C (en) | 2013-03-13 | 2022-08-02 | University Of Maryland | Advanced functional biocompatible polymer putty used as a hemostatic agent for treating damaged tissue and cells |
EP3569262A1 (en) | 2013-03-14 | 2019-11-20 | Tricol Biomedical, Inc. | Biocompatible and bioabsorbable derivatized chitosan compositions |
US9192574B2 (en) | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan paste wound dressing |
US9192692B2 (en) | 2013-10-24 | 2015-11-24 | Medtronic Xomed, Inc. | Chitosan stenting paste |
EP3074026B1 (en) * | 2013-11-25 | 2020-01-08 | D.T.R. Dermal Therapy Research Inc. | Composition, system and method for treating skin |
WO2015098864A1 (en) * | 2013-12-24 | 2015-07-02 | 株式会社グリーンエバー | Gel-forming agent containing sulfonamide and chitosan and having a powdered dosage form |
US9259357B2 (en) | 2014-04-16 | 2016-02-16 | Loma Linda University | Composition, preparation, and use of chitosan shards for biomedical applications |
CN104258451B (en) * | 2014-05-19 | 2016-03-02 | 山东省医疗器械研究所 | A kind of grafted chitosan bleeding-stopping dressing with three-dimensional Multi-network and preparation method thereof |
US20160082037A1 (en) * | 2014-09-23 | 2016-03-24 | Loma Linda University Medical Center | Composition, preparation, and use of chitosan powder for biomedical applications |
JP6333715B2 (en) * | 2014-12-19 | 2018-05-30 | 国立大学法人鳥取大学 | Wound healing promoter |
IL267432B1 (en) * | 2016-12-22 | 2024-03-01 | Omrix Biopharmaceuticals Ltd | Hemostatic composition comprising an anion exchanger and a calcium salt |
KR101878769B1 (en) | 2017-04-03 | 2018-08-16 | 조석형 | Low molecular CM-β-1,3-Glucan calcium salt hemostatic agent powder |
WO2019211483A1 (en) * | 2018-05-04 | 2019-11-07 | Bonoss Medical Aktiebolag | A composition for reduction of scar formation |
KR101939944B1 (en) | 2018-05-04 | 2019-04-11 | 이근학 | Hemostatic dressing member and method for preparing the same |
US10517988B1 (en) | 2018-11-19 | 2019-12-31 | Endomedix, Inc. | Methods and compositions for achieving hemostasis and stable blood clot formation |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3632754A (en) * | 1968-02-12 | 1972-01-04 | Lescarden Ltd | Use of chitin for promoting wound healing |
US3911116A (en) * | 1970-04-13 | 1975-10-07 | Leslie L Balassa | Process for promoting wound healing with chitin derivatives |
US3914413A (en) * | 1971-02-10 | 1975-10-21 | Leslie L Balassa | Process for facilitating wound healing with N-acetylated partially depolymerized chitin materials |
US3989535A (en) * | 1974-02-11 | 1976-11-02 | American Cyanamid Company | Solution of poly(N-acetyl-D-glucosamine) |
JPS5626049A (en) * | 1979-08-06 | 1981-03-13 | Mitsubishi Rayon Co | Chitine or chitine derivative nonwoven fabric and method |
US4394373A (en) * | 1981-04-06 | 1983-07-19 | Malette William Graham | Method of achieving hemostasis |
-
1982
- 1982-11-08 US US06/440,039 patent/US4532134A/en not_active Expired - Lifetime
-
1983
- 1983-06-10 CA CA000430203A patent/CA1222698A/en not_active Expired
- 1983-06-14 DE DE3321446A patent/DE3321446C2/en not_active Revoked
- 1983-06-16 GB GB08316364A patent/GB2129300B/en not_active Expired
- 1983-07-07 JP JP58122467A patent/JPS5988424A/en active Granted
Also Published As
Publication number | Publication date |
---|---|
JPH054369B2 (en) | 1993-01-19 |
DE3321446A1 (en) | 1984-05-10 |
GB8316364D0 (en) | 1983-07-20 |
DE3321446C2 (en) | 1993-10-07 |
US4532134A (en) | 1985-07-30 |
GB2129300B (en) | 1986-04-03 |
JPS5988424A (en) | 1984-05-22 |
GB2129300A (en) | 1984-05-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA1222698A (en) | Method of achieving hemostasis, inhibiting fibroplasia, and promoting regeneration in a tissue wound | |
DE60009275T2 (en) | PLASTIC PLANT FROM EXPANDED POLYTETRAFLUOROETHYLENE WITH ONE COATING | |
DE69534759T2 (en) | Polyanionic polysaccharides and hydrophobic bioabsorbable polymer-containing compositions | |
DE69728054T2 (en) | BIORESORABLE SEALING POINTS FOR POROUS ARTIFICIAL VESSELS | |
US5116824A (en) | Biomaterial comprising a composite material of a chitosan derivative and collagen derivative | |
US4787900A (en) | Process for forming multilayer bioreplaceable blood vessel prosthesis | |
US4902289A (en) | Multilayer bioreplaceable blood vessel prosthesis | |
US4563490A (en) | Composite polymeric material for biological and medical application and the method for its preparation | |
US6015844A (en) | Composite surgical material | |
US5632776A (en) | Implantation materials | |
DE69817574T2 (en) | MANUFACTURING METHOD FOR A FIBER-FREE, POROUS MATERIAL | |
Zhu et al. | Blood compatibility of chitosan/heparin complex surface modified ePTFE vascular graft | |
WO1983003536A1 (en) | A multilayer bioreplaceable blood vessel prosthesis | |
DE2631908A1 (en) | NETWORKED POLYMER | |
CA2004740A1 (en) | Low molecular weight heparin, heparinoid and hexuronyl hexosaminoglycan sulfate containing adhesion prevention barrier and process | |
CA2471994A1 (en) | Hemostatic compositions and methods for controlling bleeding | |
US20090214667A1 (en) | Medical technical product, method for producing the same and providing the same for surgery | |
AU745199B2 (en) | Sulphated hyaluronic acid and sulphated derivatives thereof covalently bound to polyurethanes, and the process for their preparation | |
EP2812037B1 (en) | Biodegradable non-woven material for medical purposes | |
CA2129070C (en) | Composite surgical material | |
JP5366350B2 (en) | Production method and use of chitosan film having high cell adhesion ability, and product coated with the film | |
JP2015535192A (en) | Improvement of tissue sealant for bleeding that cannot be compressed | |
WO2002030480A1 (en) | Biocompatible composite material for medical applications | |
Perego et al. | Functionalization of poly-L-lactic-co-ε-caprolactone: Effects of surface modification on endothelial cell proliferation and hemocompatibility | |
CN109464701B (en) | Preparation method of VA @ PLGA-CS-HA composite antibacterial slow-release microspheres and application of VA @ PLGA-CS-HA composite antibacterial slow-release microspheres in bone repair scaffold material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MKEX | Expiry |